BioMark Diagnostics Inc.
BMKDF
$0.45
$0.023.55%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -42.18% | -24.29% | -7.04% | -8.43% | -6.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -42.18% | -24.29% | -7.04% | -8.43% | -6.45% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -42.18% | -24.29% | -7.04% | -8.43% | -6.45% |
| SG&A Expenses | -17.18% | -23.69% | -9.96% | 31.38% | 25.49% |
| Depreciation & Amortization | 95.98% | 44.15% | 22.37% | -2.37% | -31.22% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.84% | -17.45% | -4.97% | 14.01% | 6.26% |
| Operating Income | -0.34% | 16.91% | 4.78% | -16.17% | -7.44% |
| Income Before Tax | 12.21% | 18.16% | -2.80% | -31.39% | -21.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 12.21% | 18.16% | -2.80% | -31.39% | -21.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.21% | 18.16% | -2.80% | -31.39% | -21.76% |
| EBIT | -0.34% | 16.91% | 4.78% | -16.17% | -7.44% |
| EBITDA | -0.32% | 17.09% | 4.90% | -16.23% | -7.42% |
| EPS Basic | 11.45% | 42.94% | 24.64% | 0.00% | 3.68% |
| Normalized Basic EPS | 12.20% | 43.14% | 24.42% | 0.00% | 3.53% |
| EPS Diluted | 11.45% | 42.94% | 24.64% | 0.00% | 3.68% |
| Normalized Diluted EPS | 12.20% | 43.14% | 24.42% | 0.00% | 3.53% |
| Average Basic Shares Outstanding | -63.52% | 240.81% | 244.21% | 247.75% | 244.38% |
| Average Diluted Shares Outstanding | -63.52% | 240.81% | 244.21% | 247.75% | 244.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |